KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EBIT (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of EBIT readings, the most recent being $652.0 million for Q1 2026.

  • On a quarterly basis, EBIT rose 25.63% to $652.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.3 billion, a 427.42% increase, with the full-year FY2025 number at $2.2 billion, up 811.88% from a year prior.
  • EBIT hit $652.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from $300.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $882.0 million in Q3 2025 to a low of -$967.0 million in Q2 2022.
  • Median EBIT over the past 5 years was -$5.0 million (2024), compared with a mean of $43.6 million.
  • Biggest five-year swings in EBIT: tumbled 1576.92% in 2024 and later skyrocketed 9200.0% in 2025.
  • Teva Pharmaceutical Industries' EBIT stood at -$940.0 million in 2022, then soared by 180.43% to $756.0 million in 2023, then tumbled by 103.84% to -$29.0 million in 2024, then soared by 1134.48% to $300.0 million in 2025, then skyrocketed by 117.33% to $652.0 million in 2026.
  • The last three reported values for EBIT were $652.0 million (Q1 2026), $300.0 million (Q4 2025), and $882.0 million (Q3 2025) per Business Quant data.